Cloning and characterization of the 5'-flanking sequence for the human DNA topoisomerase II beta gene

Gene

Volumn 203, Issue 2, 1997, Pages 113-119

  Ng, Shu Wing ^a   Liu, Yan ^a   Schnipper, Lowell E ^a  

^a HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

Drug target; Genomic clone; Promoter; Transcriptional regulation

Indexed keywords

ADENINE; DNA TOPOISOMERASE (ATP HYDROLYSING); GUANINE;

ARTICLE; CONTROLLED STUDY; DNA FLANKING REGION; DRUG RESISTANCE; GEL MOBILITY SHIFT ASSAY; GENE DELETION; GENE EXPRESSION REGULATION; GENE SEQUENCE; HUMAN; MOLECULAR CLONING; PRIORITY JOURNAL; PROMOTER REGION; START CODON; TATA BOX; TRANSCRIPTION INITIATION;

ANTIGENS, NEOPLASM; BASE COMPOSITION; BASE SEQUENCE; CLONING, MOLECULAR; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; GENE EXPRESSION; HELA CELLS; HUMANS; ISOENZYMES; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); RESTRICTION MAPPING; RIBONUCLEASES; SEQUENCE ANALYSIS, DNA; SEQUENCE DELETION; SEQUENCE HOMOLOGY, NUCLEIC ACID; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 0030773521     PISSN: 03781119     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-1119(97)00500-3     Document Type: Article

References (35)

1. Alder H., Yoshinouchi M., Prystowsky M.B., Appasamy P., Baserga R. A conserved region in intron 1 negatively regulates the expression of the PCNA gene. Nucleic Acids Res. 20:1992;1769-1775.
2. Andoh, T., Ikeda, H., Oguro, M. (Eds.), 1993. Molecular Biology of DNA Topoisomerases and its Application to Chemotherapy. CRC Press, Boca Raton, FL.
3. Beck J., Handgretinger R., Dopfer R., Klingebiel T., Niethammer D., Gekeler V. Expression of mdr1, mrp, topoisomerase II alpha/beta, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. Br. J. Haematol. 89:1995;356-363.
4. Bugg B.Y., Danks M.K., Beck W.T., Suttle D.P. Expression of a mutant DNA topoiosmerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc. Natl. Acad. Sci. USA. 88:1991;7654-7658.
5. Chan V.T.W., Ng S.-W., Eder J.P., Schnipper L.E. Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line. J. Biol. Chem. 268:1993;2160-2165.
6. Cole S.P.C., Chanda E.R., Dicke F.P., Gerlach J.H., Mirski S.E.L. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res. 51:1991;3345-3352.
7. Danks M.K., Yalowich J.C., Beck W.T. Atyptical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res. 47:1987;1297-1301.
8. Davies S.L., Popert R., Coptcoat M., Hickson I.D., Masters J.R. Response to epirubicin in patients with superficial bladder cancer and expression of the topoisomerase II alpha and beta genes. Int. J. Cancer. 65:1996;63-66.
9. Drake F.H., Hofmann G.A., Bartus H.F., Mattern M.R., Crooke S.T., Mirabelli C.K. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry. 28:1989;8154-8160.
10. Gorman C.L., Moffat L.F., Howard B. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol. 2:1982;1044-1051.
11. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:1993;385-427.
12. Hinds M., Deisseroth K., Mayes J., Altschuler E., Jansen R., Ledley F.D., Zwelling L.A. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res. 51:1991;4729-4731.
13. Hochhauser D., Stanway C.A., Harris A.L., Hickson I.D. Cloning and characterization of the 5′-flanking region of the human topoisomerase IIα gene. J. Biol. Chem. 267:1992;18961-18965.
14. Hosking L.K., Whelan R.D., Shellard S.A., Davies S.L., Hickson I.D., Danks M.K., Hill B.T. Multiple mechanisms of resistance in a series of human testicular teratoma cell lines selected for increasing resistance to etoposide. Int. J. Cancer. 57:1994;259-267.
15. Hsiang Y.-H., Wu H.-Y., Liu L.F. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res. 48:1988;3230-3235.
16. Hsieh, T.S., 1990. Mechanistic aspects of type II DNA topoisomerases. In: Cozzarelli, N.R., Wang, J.C. (Eds.), DNA Topology and Its Biological Effects. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp. 243-263.
17. Jaffrezou J.P., Chen G., Duran G.E., Kuhl J.S., Sikic B.I. Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis. J. Natl. Cancer Inst. 86:1994;1152-1158.
18. Jenkins J.R., Ayton P., Jones T., Davies S.L., Simmons D.L., Harris A.L., Sheer D., Hickson I.D. Isolation of cDNA clones encoding the β isozyme of human DNA topoisomerase II and localization of the gene to chromosome 3p24. Nucleic Acids Res. 20:1992;5587-5592.
19. Koller E., Hayman A.R., Trueb B. The promoter of the chicken alpha 2(VI) collagen gene has features characteristic of house-keeping genes and of proto-oncogenes. Nucleic Acids Res. 19:1991;485-491.
20. Kozak M. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell. 44:1986;283-292.
21. Laemmli U.K., Kas E., Poljak L., Adachi Y. Scaffold-associated regions: cis-acting determinants of chromatin structural loops and functional domains. Curr. Opin. Genet. Dev. 2:1992;275-285.
22. Lazar J., Desvergne B., Zimmerman E.C., Zimmer D.B., Magnuson M.A., Nikodem V.M. A role for intronic sequences on expression of thyroid hormone receptor alpha gene. J. Biol. Chem. 269:1994;20352-20359.
23. Leask A., Byrne C., Fuchs E. Transcription factor AP2 and its role in epidermal-specific gene expression. Proc. Natl. Acad. Sci. USA. 88:1991;7948-7952.
24. Liu L.F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58:1989;351-375.
25. Ng S.-W., Eder J.P., Schnipper L.E., Chan V.T.W. Molecular cloning and characterization of the promoter for the Chinese hamster DNA topoisomerase IIα gene. J. Biol. Chem. 270:1995;25850-25858.
26. Nordeen S.K. Luciferase reporter gene vectors for analysis of promoters and enhancers. Biotechniques. 6:1988;454-458.
27. Osheroff N. Eukaryotic topoisomerase II. J. Biol. Chem. 261:1986;9944-9950.
28. Pascal E., Tjian R. Different activation domains of Sp1 govern formation of multimers and mediate transcriptional synergism. Genes Dev. 5:1991;1646-1656.
29. Tan K.B., Dorman T.E., Falls K.M., Chung T.D.Y., Mirabelli C.K., Crooke S.T., Mao J. Topoisomerase IIα and topoisomerase IIβ genes: characterization and mapping to human chromosomes 17 and 3, respectively. Cancer Res. 52:1992;231-234.
30. Tsutsui K., Tsutsui K., Okada S., Watanabe M., Shohmori T., Seki S., Inoue Y. Molecular cloning of partial cDNAs for rat DNA topoisomerase II isoforms and their differential expression in brain development. J. Biol. Chem. 268:1993;19076-19083.
31. Watanabe M., Tsutsui K., Tsutsui K., Inoue Y. Differential expressions of the topoisomerase II alpha and II beta mRNAs in developing rat brain. Neurosci. Res. 19:1994;51-57.
32. Webb C.D., Latham M.D., Lock R.B., Sullivan D.M. Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res. 51:1991;6543-6549.
33. Woessner R.D., Mattern M.R., Johnson C.K., Drake F.H. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Diff. 2:1991;209-214.
34. Yang X., Fyodorov D., Deneris E.S. Transcriptional analysis of acetylcholine receptor alpha 3 gene promoter motifs that bind Sp1 and AP2. J. Biol. Chem. 270:1995;8514-8520.
35. Zastawny R.L., Ling V. Structural and functional analysis of 5′ flanking and intron 1 sequences of the hamster P-glycoprotein pgp1 and pgp2 genes. Biochim. Biophys. Acta. 1173:1993;303-313.